Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | F13A1 | P00488 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | FASN | P49327 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 6/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.32 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1973807 | 1.00 | PPARG (0.36) | PPARGPPARDPPARAALDH1A1MAPT | |
| SCHEMBL8631336 | 1.00 | PPARG (0.36) | PPARGPPARDPPARAALDH1A1MAPT | |
| SCHEMBL18877268 | 1.00 | PPARG (0.36) | PPARGPPARDPPARAALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL29046719 | 0.98 | PPARG (0.35) | PPARGPPARDPPARAALDH1A1MAPT | |
| SCHEMBL29277561 | 0.88 | CNR1 (0.39) | PPARGPPARDPPARAALDH1A1MAPT | |
| SCHEMBL4161786 | 0.82 | — | — | |
| SCHEMBL13384365 | 0.80 | CYP1A2 (0.54) | PPARGPPARDPPARAGRIK1GRIK2 | |
| SCHEMBL2160963 | 0.80 | CYP1A2 (0.54) | PPARGPPARDPPARAGRIK1GRIK2 | |
| SCHEMBL2160966 | 0.80 | CYP1A2 (0.54) | PPARGPPARDPPARAGRIK1GRIK2 | |
| SCHEMBL8632405 | 0.80 | CYP1A2 (0.54) | PPARGPPARDPPARAGRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115684438-B | Q-TOF-MS-based identification method for adulterated Jiang Hu palm in ginger processed pinellia tuber | 绍兴市食品药品检验研究院 | 2024-07-09 | — | — | CN | claimed |
| CN-115974849-A | Indoxyl acetamide derivative, pharmaceutical composition containing indoxyl acetamide derivative and application of indoxyl acetamide derivative | 中国药科大学 | 2023-04-18 | — | — | CN | claimed |
| CN-114478426-A | Norbornene-type benzoxazine-containing monomer and preparation method thereof | 中北大学 | 2022-05-13 | — | — | CN | claimed |
| CN-112225703-B | Medicine for treating or preventing diseases related to LRRK2 kinase or abnormal LRRK2 mutant kinase activity | 广州智睿医药科技有限公司 | 2022-03-11 | — | — | CN | claimed |
| CN-112225703-A | Medicine for treating or preventing diseases related to LRRK2 kinase or abnormal LRRK2 mutant kinase activity | 广州智睿医药科技有限公司 | 2021-01-15 | — | — | CN | claimed |
| WO-2010039535-A1 | COMPOSITIONS AND METHODS TO TREAT EPITHELIAL-RELATED CONDITIONS | META COSMETICS, LLC (US) | 2010-04-08 | — | — | WO | claimed |
| CN-122011024-A | Phosphoramidite monomer containing bio-orthogonal groups and preparation method and application thereof | 沈阳药科大学 | 2026-05-12 | — | — | CN | disclosed |
| CN-112694608-B | Six-arm polyethylene glycol derivative, preparation method and modified biological related substance | 厦门赛诺邦格生物科技股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-112423746-B | Novel antimycobacterial heterocyclic amides | 克莱斯通公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-115974849-B | Indolyloxy acetamide derivative, pharmaceutical composition containing same and application of pharmaceutical composition | 中国药科大学 | 2024-06-21 | — | — | CN | disclosed |
| CN-115010915-B | Nitrogen-branched nine-arm polyethylene glycol derivative, preparation method and modified biologically-relevant substance thereof | 厦门赛诺邦格生物科技股份有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-115348963-B | Pyridopyrimidine compound and application thereof | 暨南大学 | 2024-04-19 | — | — | CN | disclosed |
| US-20230277553-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | CORNELL UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| CN-111269205-A | Preparation method of C-aryl glycoside compound | 华侨大学 | 2020-06-12 | — | — | CN | disclosed |
| CN-110643032-A | Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance | 厦门赛诺邦格生物科技股份有限公司 | 2020-01-03 | — | — | CN | disclosed |
| WO-2016115360-A1 | C-MYC LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2016-07-21 | — | — | WO | disclosed |
| EP-2334301-A1 | MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS | Merck Serono SA (CH) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010039535-A1 | COMPOSITIONS AND METHODS TO TREAT EPITHELIAL-RELATED CONDITIONS | META COSMETICS, LLC (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010028116-A1 | MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-03-11 | — | — | WO | disclosed |
| EP-0418071-A2 | New N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase | PFIZER INC. (US) | 1991-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277553-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | BET1, BRD4, PHKB | PPARG 1373/4885PPARD 2956/4885PPARA 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.